On March 3, 2022 Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), a leading computational biology company focused on revolutionizing product discovery and development in multiple life-science based industries, reported that it will present at the 34th Annual ROTH Conference being held both virtually and in-person in Dana Point, California on March 13-15, 2022 (Press release, Evogene, MAR 3, 2022, View Source [SID1234609498]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The conference will feature on-demand online and live presentations from companies across a variety of sectors, one-on-one and small group meetings, industry panels, and fireside chats. Past conferences have drawn thousands of attendees, including institutional investors, analysts, family offices and high net-worth investors.

Evogene’s CEO, Ofer Haviv will participate in a live, in-person fireside chat on Tuesday, March 15 at 12pm PT. Furthermore, Mr. Haviv, will participate in one-on-one meetings with institutional analysts and investors throughout the days of the conference.

Investors that wish to meet in-person with Mr. Haviv, are welcome to coordinate the meeting via their Roth representatives. Alternatively, investors may contact Evogene’s investor relations team which will coordinate either a face-to-face meeting with the CEO at the conference or alternatively a virtual meeting in the weeks following.